



News Updates: May 30, 2014

Modi government

Publication: The Economic Times

Edition: National

Date: May 30, 2014

Headline: [Narendra Modi's list of top 10 priorities for the economy](#)

Synopsis: Giving special emphasis to governance, Prime Minister Narendra Modi on Thursday unveiled a top 10 priorities' list for the government. The aim is to kick-start economic growth and ensure a smooth decision making process. M Venkaiah Naidu said that Narendra Modi has directed all ministers to prepare an agenda for the first 100 days. Modi emphasised that the "most important" aspects that need to be focussed on are efficient governance, delivery and implementation of schemes and programmes, Naidu said while briefing the media on the meeting.

Similar reports in-

Mint- [Narendra Modi's 10-point plan for India](#)

Business Standard- [Modi focus on governance, asks ministers for 100-day timetable](#)

The Hindu Business Line- [Modi governance plan: 10 priorities, 100-day agenda](#)

The Indian Express- [Draw up 100-day plan, will meet one-on-one, PM Modi tells ministers](#)

The Financial Chronicle- [Modi unveils plan for maximum governance](#)

Daily News & Analysis- [Narendra Modi asks cabinet for 100-day plan, chalks out 10 priorities for government](#)

Publication: Business Standard

Edition: National

Date: May 30, 2014

Headline: [Modi govt presents opportunity to reset Indo-US ties: IACC](#)

Synopsis: The new government led by Prime Minister Narendra Modi presents an opportunity to reset Indo-US trade relations and work towards finding a solution to the contentious intellectual property rights issue, a top official of Indo-American Chamber of Commerce said today. "US government wants to have excellent relations with India. I expect the trade relationship with India to improve significantly. Unlike his predecessor (Manmohan Singh), Modi is not perceived as a pushover, US government will respect that," IACC Executive Vice President Asoke K Laha told PTI.

Drug pricing

Publication: The Times of India

Edition: National

Date: May 30, 2014

By line article: Kiran Mazumdar Shaw, Chairperson and MD, Biocon

Headline: [Fight Medical Apartheid](#)

Synopsis: Ms. Shaw criticizes Big Pharma of 'blatant discrimination' against patients by manufacturing and selling expensive and unaffordable drugs. Ms. Shaw in order to prove her point that multinational pharma companies alienates a section of patients by discriminating against them on the basis of nationality, race and economic status cites the example of Marjin Dekkers, CEO of Bayer who had earlier stated that the cancer drug was developed for western patients who can afford it.

Publication: The Economic Times

Edition: National

Date: May 30, 2014

Headline: [Cutting drug prices will deter cos from manufacturing: Kiran Mazumdar Shaw](#)

Synopsis: Biocon Chairperson and Managing Director Kiran Mazumdar Shaw today raised concerns that the new government's intention to bring down prices of essential drugs by 25-40 per cent could deter manufacturing of such medicines by companies. While taking charge, Fertiliser and Chemicals Minister Ananth Kumar had said that he would talk to pharmaceutical companies and try to bring down prices of essential drugs by 25-40 per cent. "Minister Ananth Kumar's mandate to further reduce drug prices can potentially deter quality drug makers from manufacturing essential drugs," Shaw said on the micro blogging site Twitter.

Similar reports in-

Business Standard- [Cutting drug prices will deter cos from manufacturing: Biocon chief](#)

The Asian Age- Ananth's take on drug cost kicks off row (link unavailable, scan attached)

Deccan Chronicle- Ananth's take on drug cost kicks off row (link unavailable, scan attached)

Zee News- [Cutting drug prices will deter firms from manufacturing: Shaw](#)

Publication: The Economic Times

Edition: Online

Date: May 30, 2014

Headline: [Government mulls bringing cancer, AIDS drugs under price control](#)

Synopsis: Drug prices regulator NPPA is looking at bringing medicines used for treating diseases such as cancer, AIDS and malaria under the price control mechanism. The National Pharmaceutical Pricing Authority met recently to consider ways of bringing medicines, which are not covered by the list of essential drugs, under some regulatory ambit in order to check prices, sources said.

Similar reports in-

The Times of India- [Govt mulls bringing cancer, AIDS drugs under price control](#)

Business World- [Govt Mulls Cancer, AIDS Drugs Under Price Control](#)

The Financial Express- NPPA mulls bringing cancer, AIDS drugs under price control (link unavailable, scan attached)

The New Indian Express- [Government Mulls Bringing Cancer, AIDS Drugs Under Price Control](#)

IBN Live- [Government mulls bringing cancer, AIDS drugs under price control](#)

Website: Pharmabiz

Edition: Online

Date: May 30, 2014

Headline: [NPPA fails to fix prices of 111 scheduled formulations as information scanty](#)

Synopsis: The National Pharmaceutical Pricing Authority (NPPA), which had already revised the prices of over 400 formulations as per the new Drugs Price Control Order (DPCO) 2013, now has come out with a list of 103 formulations for which prices could not be fixed as sufficient information was not available. Apart from this, the price regulator also announced that it could not fix the prices of eight formulations as the national list of essential medicine list lacked some information like strength, route of administration, dosage form etc. All these formulations were included in the Schedule-1 of DPCO and the agency was expected to fix the prices.

Drug regulation

Publication: The Economic Times

Edition: National

Date: May 30, 2014

Headline: [Pharma dept to bat for revival of bulk drug industry](#)

Synopsis: The Department of Pharmaceuticals in a presentation, it is preparing to brief Prime Minister Narendra Modi, may pitch for the revival of the domestic bulk drug industry, which has lost much of its sheen over the past decade. Citing instances of depending too much for drug raw materials from China, which has built an immense competitive edge in API (Active Pharma Ingredients, main raw materials) and intermediates, the pharma department could bat for measures to boost the domestic bulk drug sector, government officials

Publication: The Tribune

Edition: National

Date: May 30, 2014

Headline: International cell to monitor faulty drug export cases (link unavailable, scan attached)

Synopsis: The National Drug Regulatory Authority (NDRA) has constituted an international cell to monitor faulty drug export cases. Drug Controller Navneet Marwaha, while confirming the constitution of the cell, said: "Since several units in the Baddi-Barotiwala-Nalagarh (BBN) industrial belt cater to exports, the presence of an exclusive cell to monitor issues relating to exports will ensure better compliance of the laid norms."

Website: Tapan Ray.in (*Tapan J Ray, was the President and Vice-President of the Organization of Pharmaceutical Producers of India (OPPI) and the Chairman of its Marketing Committee*)

Edition: Online

Date: May 28, 2014

Headline: [Does India Believe in Two Different Drug Quality standards?](#)

Synopsis: The National Drug Regulatory Authority (NDRA) has constituted an international cell to monitor faulty drug export cases. Drug Controller Navneet Marwaha, while confirming the constitution of the cell, opined that to reap rich harvest out of the emerging gold-plated opportunity, not just coming from India, but across the world, Indian pharma does need a strong leadership with unflinching belief in business practices weaved in corporate ethics and values. Even to come out of the episodes of repeated 'Warning Letters' from US-FDA, casting aspersions on the quality of Indian drug manufacturing standards, which are mainly related to alleged fraudulent business practices, strong corporate leadership with high ethics and value standards at all level is of absolute necessity.